# AvMed

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

**Directions**: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-305-671-0200**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**Drug Requested: Sotyktu™** (deucravacitinib)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

**Member Name:** _____

**Member AvMed #:** _____ **Date of Birth:** _____

**Prescriber Name:** _____

**Prescriber Signature:** _____ **Date:** _____

**Office Contact Name:** _____

**Phone Number:** _____ **Fax Number:** _____

**DEA OR NPI #:** _____

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

**Drug Form/Strength**: _____

**Dosing Schedule**: _____ **Length of Therapy:** _____

**Diagnosis:** _____ **ICD Code:** _____

**Weight:** _____ **Date:** _____

**NOTE:** The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ **Diagnosis: Moderate-to-Severe Plaque Psoriasis**
  **Dosing: Oral: 6 mg once daily**
  - ❑ Member has a diagnosis of **moderate-to-severe chronic plaque psoriasis**
  - ❑ Prescribed by or in consultation with a **Dermatologist**
  - ❑ Member is 18 years of age or older

**(Continued on next page)**

- ❑ Member is **NOT** receiving Sotyktu™ in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants
- ❑ Member tried and failed at least **one** of either Phototherapy or Alternative Systemic Therapy for at least **three (3) months (check each tried below)**:

| | |
|---|---|
| ❑ **Phototherapy**:<br>❑ **UV Light Therapy**<br>❑ NB UV-B<br>❑ PUVA | ❑ **Alternative Systemic Therapy:**<br>❑ **Oral Medications**<br>❑ acitretin<br>❑ methotrexate<br>❑ cyclosporine |

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to at least **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

| | | | |
|---|---|---|---|
| ❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz® | ❑ Enbrel® | ❑ Otezla® | ❑ Skyrizi® SQ |
| | ❑ Stelara® SQ | ❑ Taltz® | ❑ Tremfya |

  ***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred
  - ❑ Member has been established on Sotyktu™ for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Sotyktu was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

**Medication being provided by Specialty Pharmacy – Proprium Rx**

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****